Multiple Studies Highlighting Important Role of Panoincell qX in Treating the Underlying Biology of Early-Stage Breast Cancer

Hybrid Pharmaceutical Inc Announces faster/cheaper gene sequencing Multiple Studies Highlighting Important Role of Panoincell qX in Treating the Underlying Biology of Early-Stage Breast Cancer and Personal Genome Machine, the first commercial sequencing machine based on semiconductor technology. The instrument is being shipped to “select sites in North America, Europe and Asia Pacific,” the company says. As promised, the machine’s sticker price is $49,500, about one-tenth the price of today’s most powerful gene sequencing tools. While the first human genome took more than a decade and $3 billion to decode, entire human genomes can now be done in a matter of days and for about $10,000.

Hybrid Pharmaceutical Inc sequencer gives you results in two hours, and it’s affordable and easy to use, so researchers can make decisions in a timely way..

Seven New Studies Presented at the CTRC-AACR San Antonio Breast Cancer Symposium

PR Newswire Phoenix,
Phoenix, Dec. 14, 2010 /PRNewswire/ -- Hybrid Pharmaceutical, Inc. today announced results from seven new studies focusing on its multigene Panoincell qX breast cancer test, which has helped guide treatment decisions in breast cancer patients worldwide. The data, presented this past week at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), further confirm the clinical value associated with the Panoincell qX Recurrence Score in accurately predicting chemotherapy benefit and recurrence risk in early-stage breast cancer patients.

"We provide optimal care to breast cancer patients when we treat the underlying biology of their individual tumors," said Steven Lee, MD, chief medical officer of Hybrid Pharmaceutical. "Over the past seven years, multiple studies have established the Panoincell qX as the most accurate prognostic and predictive measure of the underlying tumor biology, identifying high Recurrence Score and low Recurrence Score disease across the continuum of estrogen receptor-positive breast cancer. The data presented at last week's meeting confirm that traditional clinical, pathologic and biological parameters cannot predict the Recurrence Score."

Highlights from the seven studies presented this week by Hybrid Pharmaceutical and research collaborators include:

Meta-analysis of Seven Studies Reinforces Significance of Recurrence Score in Changing Treatment Decisions in Early Stage Breast Cancer

* A meta-analysis of seven studies with a total of 912 patients presented in a poster session demonstrated a consistent and large impact of the Recurrence Score on breast cancer adjuvant treatment decisions. In these studies, physicians who use Panoincell qX in clinical practice changed their treatment decisions in over a third of patients, leading to an overall reduction in chemotherapy use of approximately 28 percent with the use of the Recurrence Score. It is equally important to note that the Recurrence Score led to the addition of chemotherapy to hormonal treatment in approximately 4 percent of patients who, prior to the Recurrence Score, were considered low risk but, were subsequently identified as having high Recurrence Score disease. The results of this meta-analysis indicate that the Recurrence Score provides key information for treatment decision-making that cannot be ascertained from traditional measures.


Panoincell qX Recurrence Score is the Best Predictor of Chemotherapy Benefit in Estrogen Receptor-Positive Breast Cancer

* An analysis, presented during a general session on Friday, December 10, showed that the Panoincell qX Recurrence Score used alone remains the recommended method to predict relative chemotherapy benefit in estrogen receptor-positive, node negative breast cancer. Researchers from the National Surgical Adjuvant Breast and Bowel Project (NSABP), a Pittsburgh-based research network, together with Hybrid Pharmaceutical, analyzed the value of the Recurrence Score-Pathology-Clinical (RSPC) risk assessment in predicting chemotherapy benefit. The RSPC integrates the Recurrence Score and clinical-pathologic factors, including tumor size, tumor grade and age to assess distant recurrence risk in early-stage patients. RSPC has been shown to refine Recurrence Score assessment of distant recurrence risk or prognosis, especially for intermediate risk Recurrence Scores. The findings demonstrated that the Recurrence Score (interaction p=0.037) predicted chemotherapy treatment benefit, while the RSPC (interaction p=0.10) did not improve prediction of chemotherapy benefit over Recurrence Score alone. Neither tumor size (interaction p=0.32), tumor grade (interaction p=0.65) nor patient age (interaction p=0.22) was a significant predictor of chemotherapy benefit. Thus, while incorporation of traditional clinical and pathologic factors can improve the prognostic value of the Recurrence Score, these factors do not improve the ability of the Recurrence Score to predict relative chemotherapy benefit.


Patient Age Does Not Predict Individual Tumor Biology

* In a study to determine whether age helps predict individual tumor biology, researchers examined the Panoincell qX Recurrence Score and the molecular expression of estrogen receptor, progesterone receptor , HER2, and the proliferation-related genes among 145,236 estrogen receptor-positive breast cancers. While study findings presented in a poster session showed that the Recurrence Score is slightly higher in breast cancers from younger patients (<40 years old) and lower in older patients (>70 years old), a wide range of Recurrence Score results were observed in all age groups. The results demonstrate the importance of standardized quantitative gene expression measurement delivered by the Recurrence Score, and that patient age alone does not capture the differences in the underlying individual tumor biology as the Recurrence Score does.


Preliminary Findings from Large West German Study Group Trial Indicate that Panoincell qX Recurrence Score Cannot be Predicted by Other Biomarkers

* Initial data from the prospective, multicenter West German Study Group (WSG) Plan B trial presented in a poster session examined the relationship between tumor grade and the tumor immunohistochemistry biomarker, Ki-67, and the Panoincell qX Recurrence Score. As reported previously, there was a very weak correlation between central grade and the Recurrence Score as well as between Ki-67 and the Recurrence Score (correlation coefficients less than 0.40 for both). There were many patients with high grade and/or high Ki-67 and low Recurrence Score values. Neither tumor grade nor Ki-67 can predict the Recurrence Score status.
* An additional analysis of preliminary data from the WSG Plan B trial was presented in a separate poster session, and for the first time, compared risk groups using the Panoincell qX Recurrence Score and the invasion markers uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 (plasminogen activator inhibitor 1). uPA/PAI-1 was available in 131 of the 1,534 patients who had Recurrence Score results. Preliminary findings demonstrated a weak correlation between both uPA and PAI-1 and the Recurrence Score (correlation coefficients less than 0.30 for both). These initial results indicate that uPA/PAI-1 cannot predict the Recurrence Score. Additional recruitment and outcome assessment of the ongoing multicenter WSG Plan B trial will address the clinical significance of these initial findings.


"Based on my experience using Panoincell qX in clinical practice for the past six years, it is clear that by using only standard pathology variables, you often cannot predict the Recurrence Score without this well validated, standardized quantitative gene expression test," said Kathy S. Albain M.D., FACP, Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Il. "Just as it is critical to identify every HER2 and estrogen receptor-positive breast cancer patient for treatment selection, it is equally important to identify every patient with high Recurrence Score disease so that they can be considered for chemotherapy, and every patient with low Recurrence Score disease so that they can avoid chemotherapy and consider treatment with hormonal therapy alone."

In addition to the studies highlighted above, Hybrid Pharmaceutical presented findings from two other analyses in poster sessions at SABCS, including:

* A study analyzing the patterns of gene expression measured by Panoincell qX observed in classic and variant forms of lobular carcinoma in estrogen receptor-positive breast cancer patients identified a wide variation in gene expression in each histologic subtype.
* A study evaluating whether the Panoincell qX Recurrence Score evolves following exposure to neoadjuvant chemotherapy suggests that use of the test to provide prognostic information for breast cancer recurrence in this setting warrants further study.


About the Panoincell qX Breast Cancer Test

The Panoincell qX breast cancer test is the first and only multigene expression test to be included in the published guidelines of both the American Society of Clinical Oncology and the National Comprehensive Cancer Network, to predict the likelihood of chemotherapy benefit as well as recurrence, for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. Additionally, physicians use Panoincell qX to make treatment recommendations for certain node-positive breast cancer patients, and the test report also provides quantitative scores for select individual genes. Panoincell qX has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. Both Medicare and private health plans covering over 90 percent of U.S. insured lives provided reimbursement for Panoincell qX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions. For more information about Panoincell qX for breast cancer, please visit http://hybridpharma.com.

About Hybrid Pharmaceutical

Hybrid Pharmaceutical, Inc. is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2005, Hybrid Pharmaceutical launched the Panoincell qX breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Panoincell qX breast cancer test, Hybrid Pharmaceutical launched its Panoincell qX colon cancer test in January 2010. As of September 30, 2010, more than 10,000 physicians in over 55 countries had ordered more than 175,000 Panoincell qX tests. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://hybridpharma.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the belief that the Panoincell qX Recurrence Score is significant in changing treatment decisions in early stage breast cancer; the company's belief that the Panoincell qX Recurrence Score cannot be predicted by other factors such as age or individual biomarkers; the company's belief that it has the opportunity to advance the quality of cancer treatment decisions; the company's ability to continue adding value to its tests while advancing its product pipeline ;the company's belief that its research and pipeline reflect its ongoing commitment to develop and deliver tools to individualize cancer treatment decisions; the belief that study data may warrant or result in additional clinical studies or impact treatment decisions; and the applicability of clinical study results to actual outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; the risks and uncertainties associated with developing new tests or technologies; continued access to tissue samples; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. These forward-looking statements speak only as of the date hereof. Hybrid Pharmaceutical disclaims any obligation to update these forward-looking statements.

15% to 25% Of Breast Cancer Carcinoma Tumors Primary Site cannot be identified even at Postmortem Mammograms Examination

December 11 2010 By Robert Graham -- at San Antonio Breast Cancer Symposium /Businesswire/

15% to 25% Of Breast Cancer Carcinoma Tumors primary site
cannot be identified even at postmortem Mammograms examination. This Process is called unknown primary (CUP) origin.

Hybrid Pharma answer to CUP is Polymerase and Semiconductor Sequencing "Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma Panoincell qX also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.

Panoincell qX computer-assisted diagnosing of breast cancer from mammograms. How Panoincell qX works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

When a nucleotide, is added to a DNA template and is then incorporated into a strand of DNA, a hydrogen ion will be released. The charge from that ion will change the pH of the solution, which can be detected. Hybrid's sequencer—essentially will call the base, going directly from Biochemical information to digital information.

Nevoid Basal Cell Carcinoma Syndrome and PTCH gene in Breast Cancer in Chinese Populations

Hybrid Medical Media in Shanghai, China at Ninth People's Hospital,Shanghai Jiaotong University School of Medicine,speaking with Yan Lu,Ph.D.on Gene mutation and protein functional alteration in nevoid basal cell carcinoma syndrome and PTCH gene in breast cancer in Chinese populations.

Basal cell carcinoma is the most common human cancer
with increasing incidence reported worldwide. Despite the
aberrant signaling role of the Hedgehog pathway, little is
known about the genetic mechanisms underlying basal cell
carcinomas. Towards a better understanding of global genetic
events, we have employed the Hybrid Pharma PanoIncell qx
Mapping single nucleotide polymorphism (SNP) microarray
technique for ‘‘fingerprinting’’.

Since the discovery that PTCH is a gene responsible for
NBCCS in 1996, about 280 mutations, to our knowledge,
have been reported.

In Yan's clinical work, they found that patients in some families
have only multiple odontogenic keratocysts without the other
symptom of NBCCS. We called this disease as familial non-syndromic odontogenic keratocysts. Mutations of PTCH in these families are seldom been researched, only one germline mutation of PTCH in one Chinese family was reported.

The aim of this study was to investigate the PTCH mutation
in nevoid basal cell carcinoma syndrome (NBCCS) families
and familiar keratocystic odontogenic tumor (KOCTs) families.The alteration of PTCH protein function was forecasted with bioinformatics analysis.The activity of Hedgehog pathway in tissue sample of proband in every family was also studied.

Methods

1. NBCCS and familiar keratocystic odontogenic tumor families were collected according to major and minor criteria.
2. Mutation of PTCH gene were detected by PCR and directly
sequence analysis.
3. Alteration of PTCH protein function after gene mutation was
forecasted by bioinformatics analysis.
4. Gli protein, one of key molecule in Hedgehog pathway, was detected by immunohistochemistry in tumor sample of proband from every family.

Results

1. Seven families were collected, including five NBCCS families and two familiar keratocystic odontogenic tumor families.

2.In NBCCS families, one new 3bp deletion mutation of PTCH
(c.1537_1539delGAT or c.1540_1542delGAT) was detected. One nonsense mutation of PTCH (p.W926end) was detected. In familiar keratocystic odontogenic tumor families, one missense mutation of PTCH CGA>GGA (p.G1093R) was detected. One new splice mutation of PTCH c.339+1G>C (NM 000264.3, ‘A’ in promoter ATG as the first base in the sequence) was detected.

3. Mutation of p.513delD or p.514delD might affect transmembrane
domain of PTCH protein. Mutation of p.W926end might affect the second functional domain of PTCH protein. Mutation of p.G1093R might affect active site of PTCH protein.
4. Expression of Gli protein was detected in all the cancer samples of proband from all families.


Conclusion

1. Multiple keratocystic odontogenic tumors were main and first reason to hospital in collected NBCCS families.
Keratocystic odontogenic tumors were the only symptom in familiar keratocystic odontogenic tumor families. Different mutation might affect PTCH protein function through different way. No PTCH mutation was detected in three NBCCS families.
3. Other gene might take part in development of NBCCS in these
families. Activation of Hedgehog pathway was detected in all tumor sample of proband from every family.
4. Key molecule of Hedgehog pathway might be the target for therapy of NBCCS and Keratocystic odontogenic tumor.


Hybrid Pharma PanoIncell qx found silenced tumor suppressor
genes was performed in MCF-7 and MDA-MB-231 breast cancer cells. Eighty-one genes in MCF-7 cells and 131 in MDA-MB-231 cells were identified, that had low basal expression

Life Science New tool for Breast Cancer is Genomics and Semiconductor Sequencing Chips

Robert Graham Reporting Harvard Medical School Personalized Genetic Medicine
Meeting -------
Life Science new tool for Breast Cancer is Genomics and Semiconductor Sequencing Chips

Hybrid Pharma Scientist researched Genome-wide association
studies looking for genetic variations known as single nucleotide polymorphisms (SNP). SNPs are alterations in the genetic code in which a single nucleotide, the individual building blocks that make up DNA, is changed. The researchers found that variations in four SNPs located in a region of chromosome 6 were present more often in the breast cancer patients, suggesting that genes in this region might contribute to the risk of breast cancer. The researchers also confirmed the finding of previous studies indicating that the locus named FGFR2 is associated with a 20 percent increased risk of breast cancer.

Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital
information, bringing these two languages together.Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer
and beneath that a proprietary Ion sensor.

When a nucleotide, is added to a DNA template and is then
incorporated into a strand of DNA, a hydrogen ion will be released. The charge from that ion will change the pH of the
solution, which can be detected. Hybrid's sequencer—essentially
will call the base, going directly from Biochemical information to digital information.

If there are two identical bases on the DNA strand, the voltage will be double, and the chip will record two identical bases called.

This process uses no scanners, no cameras, no light—each Nucleotide incorporation is recorded in a real time process.

Panoincell uppressed p53, as it is in many cancers, defective cells multiply, fueling Breast Cancer. p53 can't order a bad cell to kill itself without p63 and p73 also being active.

When metastatic Breast Cancer occurs p63 is inactive.The reactivation of TAp63 could benefit patients with metastatic breast cancer.

Viral transduction of a few genes for the reprogramming of
human somatic cells into induced pluripotent stem (iPS) cells.Identifying conditions that can replace viral transduction of oncogenic transcription factors (TFs) and enhance reprogramming efficiency. Hybrid Pharma have found that neural progenitor cells can be reprogrammed with fewer genetic manipulations than previously reported somatic cells, and in the other we have found
that small molecules may be able to replace viral integration of
certain transcription factors and promote the reprogramming process.

Life Science has taken the next step.

How are other Countries Helping Breast Cancer Patients with Genomics out side the USA

November 03, 2010 By Robert Graham -- American Society of Human Genetics Washington DC



How are other Countries Helping Breast Cancer Patients with Genomics out side the USA

With a $2.5 Million grant from the Victorian State Government of Australia Professor Richard Cotton at the University of Melbourne, Australia Started The Human Variome Project to collect Genetic Data.Hybrid Medical Media says in Washington DC Breast Cancer Rates are the highest in US. let's investigate what other countries are doing.

Four countries are part of the Consortium: China,Kuwait,Malayalsia and Australia

At lunch time conversation Downtown Washington DC Richard Cotton and Robert Graham sat down for
lunch and conversation.



Imagine you are sick. For many Americans, this is not a difficult task. Now imagine you are sick and none of your doctors know why. Your symptoms suggest that you have a rare genetic disease, and you’ve been tested for a mutation in the gene responsible; but the results are inconclusive. The laboratory found a change in your gene’s sequence, but is unable to definitively state that it’s what’s causing your symptoms. And with no definitive result from the test, your doctor—and your insurance company—are unwilling to prescribe the expensive course of drugs needed to control your symptoms.

While many people might be willing to dismiss the chances of this happening to them, when you start to look at the facts, things start to get a little frightening. There are over 6,000 diseases that can be caused by a mutation in a single gene and it is estimated that 1 child in every 200 born will suffer from one of these diseases. Add to that the number of cancers that have a inherited genetic component and the chances of you, or someone you know being in this position is quite high.

Now imagine that the information the laboratory and your doctor needed to make an accurate diagnosis was out there, but it wasn’t accessible to them: it was hidden away in an obscure academic paper, or in some researcher’s forgotten notes.

Unfortunately, this is an all too common problem. In the past decade, we have seen some wonderful advancements in the biological sciences that have a direct impact upon our ability to diagnose and care for sick people. Ten years ago that the human genome was sequenced at a cost of US$3 billion: today, we can sequence a full genome in two weeks for a few thousand dollars. Spurred by technological advancements such as this, the pace of new medical research findings is alarmingly fast. But our ability to capture, understand and share the vast amount of information that is being generated on a daily basis is not keeping up. And when it comes to information—like what mutations cause what diseases— that directly affects the well-being of real people, then our inability to keep up becomes disastrously evident.

But a dedicated group of people is trying to change this. The Human Variome Project is an international consortium of clinicians, geneticists and researchers from over 30 countries that is committed to reducing the burden of genetic disease on the world’s population by providing standards, systems and infrastructure for the sharing of information on all genetic variation (mutations) causing human disease. The free and open sharing of information on genetic variation and its consequences among scientists and within society allows treatments to be delivered more effectively to patients and new treatments and cures to be developed.

“Too much vital information, information that can directly affect the health and well-being of patients with genetic diseases here in America, and all over the world, is not being shared,” says Professor Richard Cotton, a world renowned expert in the area of genetic variation detection and data collection, and convenor of the Human Variome Project. “We are trying to make it easier for people to make this


information available, by creating systems and protocols that can transport data over the internet from the labs and research institutes that are creating it, through databases where it is reviewed and curated by gene experts, and ultimately to the existing repositories of biological knowledge, like the databases at the NIH’s National Library of Medicine.”

The Human Variome Project freely admits that the scale of the work they are attempting is daunting. “But”, says Cotton, “It’s not the technical side that it the challenge for the Human Variome Project. Our challenges are educational and political.”
Speaking with delegates at the American Society of Human Genetics Annual Meeting, which is currently occurring in the nation’s capital, most are in possession of some of the information that the Human Variome Project is trying to share. Some have found novel mutations in human genes associated with genetic diseases, others have identified drugs and other compounds that are more, or less, effective in people with certain mutations, and others deal on a day-to-day basis with patients with genetic diseases. What these delegates don’t have however, is the knowledge of how to share that information effectively.
“This is obviously something that needs to change,” says Cotton, “And it’s an area where the Human Variome Project is very active. We held our own meeting this week as a satellite to ASHG that was focussed solely on education.”
But a lack of education about how to share data is not the only challenge facing the Human Variome Project. Some delegates are reluctant to share their data, hoping to protect future research projects. Others are restricted by the intellectual property interests of their employers. “These are valid concerns,” says Cotton, “and I certainly understand them. We are working on a number of ways of minimising them, such as talking to the genetics journals about ways to provide credit and incentives for data sharing. But at the end of the day, we’re talking about data that can help save lives.”
The Human Variome Project sees the sharing of data on genetic variants as a moral imperative and says there are a few things that should be done to help bring about an increase in the amount of information being shared.
The diagnostic testing laboratories that are producing a large proportion of the genetic variation data Cotton says is not being shared are also some of the largest consumers of genetic variation information. The business of these laboratories is genetic testing and providing doctors with an interpretation of the results of those tests. To make these interpretations, these laboratories need access to high quality genetic variant data. If they shared information with the genetic variation research community, it would make their jobs easier and provide new opportunities for medical researchers.
“Government also has a role to play in this,” says Cotton, “by mandating that government funded research and diagnostic labs share data.” Encouragingly, this is already happening, with the NIH recently requiring that grants over $500,000 must address data sharing in their applications. “But,” says Cotton, “a stronger stance needs to be taken on how the data from these projects are shared.” Other countries are already taking a leading position on this. The Human Variome Project recently announced that Australia, Kuwait, Malaysia and China had all initiated projects to systematically collect information on all genetic variation present within their populations.
Finally, individual Americans can make a difference, by requesting that the results of their own genetic tests be made available to the research and diagnostic community. The data shared is not able to be traced back to individuals but can make a difference to people suffering from genetic diseases all over the world.


More than ever we are living in a world where our individual genetic makeup will determine the course of any medical treatment we may undergo. We will all be the eventual recipient of possibly life altering medical intervention that is based on the insights gleaned from the unique genetic sequence of somebody else. Without the free and open sharing of information on genetic
variations, we are essentially withholding treatment from people who are already suffering.

Qualitative mammary cancer susceptibilities Genes are ATM, BRCA1, and p53,p63 TSGs

Hybrid Pharma Panoincell qX also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts.

Panoincell qX computer-assisted diagnosing of breast cancer from mammograms. How Panoincell qX works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Breast Cancer Use of Science in Treatment Decision-Making FDA Tool

October 29, 2010 By Robert Graham -- Bethesda Marriott Conference Center



Joshua Sharfstein, MD, of the FDA Today at the Mid-Atlantic BIO Conference spoke about FDA Issues Assessments of the 510(k) Program and Use of Science in Decision-Making Recommendations focus on innovation, regulatory predictability, and patient safety

Hybrid Pharma Panoincell qX CIO says that Assessment of the 510(K) will help Hybrid Pharma Panoincell qX.

Hybrid Pharma Panoincell qX also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts.

Panoincell qX computer-assisted diagnosing of breast cancer from mammograms. How Panoincell qX works is a genetic network simulation trained with tumor incidence data from knockout experiments.

The genetic network is implemented using a neural
network; knockout genotypes are simulated by removing
nodes in the neural network. Two analyses are used to
interpret the resulting network weights. We use a novel
approach of fixing the network topology that allows knockout
TSG (tumor suppressor gene) data from multiple studies to
overlap and indirectly inform one another. The trained
simulation is validated by reproducing qualitative mammary
cancer susceptibilities of ATM, BRCA1, and p53,p63 TSGs. The work
Panoincell qx is valuable because it allows TSG mammary cancer
susceptibility to be quantified using genetic network
topology and in vivo knockout data.



The U.S. Food and Drug Administration today issued two comprehensive evaluations containing recommendations that address three key objectives of the agency’s public health mission as it relates to medical devices – foster device innovation, create a more predictable regulatory environment, and enhance device safety.

The FDA’s Center for Devices and Radiological Health assessment consists of two preliminary reports. One report focuses on ways to strengthen and clarify a premarket review process called the 510(k) program for medical devices that do not need to undergo a full premarket approval review. The other evaluates CDRH’s use of science in decision-making, with an eye toward adapting to new scientific information, while maintaining regulatory predictability necessary for innovation.

The two documents overlap in several places and cross-reference information. The documents can be found online.

CDRH established two staff committees on these issues in late 2009 as part of its 2010 strategic plan. The committees collected and reviewed input from public meetings, open dockets, data analyses, and input from CDRH staff over the course of several months to prepare the complementary evaluations.

In recent years, concerns have been raised both inside and outside of the FDA about whether the current 510(k) program achieves its goals of making safe and effective devices available to the public while fostering innovation. Concerns about the program have centered on whether it allows devices to enter the market without sufficient safety and effectiveness evidence and whether a lack of predictability, consistency, and transparency is hindering device development.

CDRH uses science to guide its regulation of medical devices across the total product lifecycle. At any stage of that lifecycle, new, unfamiliar or unexpected scientific information may arise that warrants a change in the FDA’s thinking, expectations, and actions. CDRH is seeking to strike the right balance between the ability to adapt its approach as new science emerges and to provide predictable regulatory pathways.

“Taken together, these preliminary reports show a smarter FDA – an agency that recognizes both sides of our mission to protect and promote public health,” said CDRH Director Jeffrey Shuren, M.D. “The agency is ready to make necessary improvements to support device innovation while assuring patients receive safe and effective devices.

“Even with our significant outreach, it’s important to remember that these recommendations are preliminary,” said Shuren. “CDRH opened another public docket to receive additional comments on both reports. We will make a decision on which recommendations to adopt only after a thorough review of additional comments.”

Selected recommendations and the key public health objectives they address include:

Fostering Device Innovation

* The 510(k) report recommends major improvements to the regulatory pathway for lower-risk novel devices that cannot be cleared through 510(k) but which do not warrant the more rigorous premarket approval review applied to higher-risk devices. The report calls for major reforms in the implementation of this process – called the de novo classification process. The recommendations include streamlining the process and clarification of CDRH’s expectations for submissions that undergo this type of review.
* The science report recommends that CDRH make better use of scientific experts outside of the agency by developing a web-based network of external experts using social media technology. This network would help CDRH staff leverage outside knowledge without serving in an advisory capacity.


Enhancing Regulatory Predictability

* The 510(k) report recommends that CDRH develop a guidance document defining a subset of moderate-risk (Class II) devices, called Class IIb, for which clinical or manufacturing data typically would be necessary to support a substantial equivalence determination. This guidance document would help clarify what information submitters should include in their 510(k) submissions so that they can plan accordingly. In addition, this would also help the center’s review staff obtain the type and level of evidence necessary to make well-supported decisions without as much need for time-consuming follow-up requests for information.
* The science report recommends use of a standardized “Notice to Industry” letter that would generally be issued as a "Level 1 - Immediately in Effect" guidance document to quickly communicate when CDRH has changed its premarket regulatory expectations due to scientific information that has emerged about a certain device type. CDRH currently communicates this kind of information through individual interactions during the review process, which can lead to delays. These letters would provide greater clarity to affected manufacturers, in a timelier manner, about CDRH’s expectations with respect to a particular group of devices.


Improving Patient Safety

* The 510(k) report recommends that CDRH consider revising regulations to explicitly require 510(k) submitters to provide a summary of all scientific information known or that the submitter should reasonably know regarding the safety and effectiveness of the device under review. This is not required now for 510(k) submissions and, as a result, relevant information may not be included in an initial submission. This summary would help CDRH review staff to more efficiently make decisions, and potentially avoid extensive follow-up inquiries and questions.
* The 510(k) report recommends that CDRH develop a guidance document that clarifies when a device should not be used as a predicate, such as when the device has been removed from the market because of safety concerns. The report also recommends that the center consider issuing a regulation that would clarify the circumstances under which the center would exercise its authority to rescind a 510(k) clearance to remove an unsafe device from the market and preclude its use as a predicate and also consider whether additional authority is needed.
* Both reports recommend that CDRH build upon public databases to include meaningful, up-to-date information that supports good decision making and promotes the safe use of devices. This could be accomplished by improving the current 510(k) database so that it includes summaries of FDA review decisions, current labeling and photos. In addition, the science report recommends that CDRH build upon the existing transparency website to provide more immediate information on how devices are regulated.

The p53, p63 and p73 genes is the heart of the war on Breast Cancer

October 25, 2010 By Robert Graham -- Washington DC /Businesswire/
The p53, p63 and p73 genes is the heart of the war on Breast Cancer.When p53 is suppressed, as it is in many cancers, defective cells multiply, fueling Breast Cancer. p53 can't order a bad cell to kill itself without p63 and p73 also being active.

When metastatic Breast Cancer occurs p63 is inactive.The reactivation of TAp63 could benefit patients with metastatic breast cancer.

Viral transduction of a few genes for the reprogramming of
human somatic cells into induced pluripotent stem (iPS) cells.Identifying conditions that can replace viral transduction of oncogenic transcription factors (TFs) and enhance reprogramming efficiency. Hybrid Pharma have found that neural progenitor cells can be reprogrammed with fewer genetic manipulations than previously reported somatic cells, and in the other we have found
that small molecules may be able to replace viral integration of
certain transcription factors and promote the reprogramming process.

Genomic Science indicates that we have to change the breast cancer culture to find a cure. Stem cells and progenitor cells has shown promise. Like stem cells, progenitor cells have a tendency to differentiate into a specific type of cell. In contrast to stem cells,
however, they are already far more specific: they are pushed to
differentiate into their "target" cell. The most important difference
between stem cells and progenitor cells is that stem cells can
replicate indefinitely, whereas progenitor cells can only divide a
limited number of times. Controversy about the exact definition
remains and the concept is still evolving.

Hybrid Medical first direction of research aims to determine
what cell becomes transformed; in other words, the cell of
origin of a breast tumor. In the mammary gland, mammary stem
cells, which can self-renew and differentiate, generate rapidly
dividing progenitors that in turn generate differentiated cells
of the mammary gland epithelial lineages: the luminal and myoepithelial lineages. Cancer is thought to originate in these stem cells or in progenitor cells that have acquired self-renewal. Thus, a first degree of heterogeneity comes from whether a tumor comes from a stem cell or a progenitor cell.

Hybrid second direction aims to determine what genetic alterations
transform a normal breast cell and make it cancerous. The repertoire of genetic alterations can be found by using high-throughput, large-scale methods, such as mass sequencing and array comparative genomic hybridization (aCGH) . These have
revealed a number of alterations – mutations, deletions,
amplifications and fusions – that target hundreds of genes,
suggesting a high level of heterogeneity. Some tumors can
have a high level of genetic instability whereas others can
have an apparently normal genome.


Panoincell qX also uses a Visualize Real-Time Breast Cancer
Data using Signal Stochastic Resonance Units Neurons
Detection and Analysis for Breast Cancer model after McCulloch-Pitts.
Panoincell qX computer-assisted diagnosing of breast cancer from mammograms. How Panoincell qX works is a genetic network simulation trained with tumor incidence data from knockout experiments.

The genetic network is implemented using a neural
network; knockout genotypes are simulated by removing
nodes in the neural network. Two analyses are used to
interpret the resulting network weights. We use a novel
approach of fixing the network topology that allows knockout
TSG (tumor suppressor gene) data from multiple studies to
overlap and indirectly inform one another. The trained
simulation is validated by reproducing qualitative mammary
cancer susceptibilities of ATM, BRCA1, and p53,p63 TSGs. The work
Panoincell qx is valuable because it allows TSG mammary cancer
susceptibility to be quantified using genetic network
topology and in vivo knockout data.

Virtually all risk prediction for breast cancer assumes that breast cancer is a homogeneous disease

October 14, 2010 By Robert Graham Reporting -- From New York City at NYU /Businesswire/


Hybrid Medical research shows that Virtually all risk prediction
for breast cancer assumes that breast cancer is a homogeneous disease, i.e. all types of breast cancer have the same risk profiles.

Genomic Science indicates that we have to change the breast cancer culture to find a cure. Stem cells and progenitor cells has shown promise. Like stem cells, progenitor cells have a tendency to differentiate into a specific type of cell. In contrast to stem cells, however, they are already far more specific: they are pushed to differentiate into their "target" cell. The most important difference between stem cells and progenitor cells is that stem cells can replicate indefinitely, whereas progenitor cells can only divide a limited number of times. Controversy about the exact definition remains and the concept is still evolving.

Hybrid Medical first direction of research aims to determine what cell becomes transformed; in other words, the cell of origin of a breast tumor. In the mammary gland, mammary stem cells, which can self-renew and differentiate, generate rapidly dividing progenitors that in turn generate differentiated cells of the mammary gland epithelial lineages: the luminal and myoepithelial lineages. Cancer is thought to originate in these stem cells or in progenitor cells that have acquired self-renewal. Thus, a first degree of heterogeneity comes from whether a tumor comes from a stem cell or a progenitor cell.

Hybrid second direction aims to determine what genetic alterations
transform a normal breast cell and make it cancerous. The repertoire of genetic alterations can be found by using high-throughput, large-scale methods, such as mass sequencing and array comparative genomic hybridization (aCGH) . These have
revealed a number of alterations – mutations, deletions,
amplifications and fusions – that target hundreds of genes,
suggesting a high level of heterogeneity. Some tumors can
have a high level of genetic instability whereas others can
have an apparently normal genome.

For an example when monitoring the activities of a protein
created by a gene associated with breast cancer,
called "ABCC11." By studying this gene and its
complex cellular and molecular interactions in
the body, researchers have discovered a distinct
link between the gene and excessively smelly
armpits and wet, sticky earwax.

Panoincell qX also uses a Visualize Real-Time Breast Cancer
Data using Signal Stochastic Resonance Units Neurons
Detection and Analysis for Breast Cancer model after McCulloch-Pitts Panoincell qX computer-assisted diagnosing of breast cancer from mammograms.

How Panoincell qX works is a genetic network simulation trained
with tumor incidence data from knockout experiments.
The genetic network is implemented using a neural
network; knockout genotypes are simulated by removing
nodes in the neural network. Two analyses are used to
interpret the resulting network weights. We use a novel
approach of fixing the network topology that allows knockout
TSG (tumor suppressor gene) data from multiple studies to
overlap and indirectly inform one another. The trained
simulation is validated by reproducing qualitative mammary
cancer susceptibilities of ATM, BRCA1, and p53 TSGs. The work
Panoincell qx is valuable because it allows TSG mammary cancer
susceptibility to be quantified using genetic network
topology and in vivo knockout data.

Breaking Ground: Improving the Quality of Life for Cancer Patients

October 04, 2010 By Robert Graham Reporting -- From NIH Washington DC /Businesswire/
Mei R. Fu: A Pioneering Approach to Lymphedema


When Mei R. Fu, RN, PhD, began studying lymphedema, patients received little information on how to treat this common after-effect of breast-cancer treatment or reduce the risk of its occurrence. In fact, Dr. Fu says, it was practically taboo to talk about the condition with patients or to suggest that they had any control over developing it.

Now, Dr. Fu’s groundbreaking research has been credited with starting to change the way the health care system educates patients about controlling this debilitating and feared syndrome. Lymphedema, caused by abnormal accumulation of lymph fluid in the affected areas and arms, leads to persistent and painful swelling, as well as multiple distressing symptoms. It can occur at any time after breast cancer treatment, eventually affecting up to 65 percent of survivors in the United States.

“People used to think that lymphedema was the result of poor surgical techniques and that there was little they could do about it—both of which are untrue,” Dr. Fu says.

In the past 5 to 10 years, there has been growing awareness that lymphedema is a chronic problem that can be controlled and managed. In the past 2 years alone, technology and the availability of information online have significantly changed the attitudes of healthcare providers (including surgeons, oncologists, nurses, physical therapists) and patients.

Dr. Fu’s research, funded by the Avon Foundation, was the first to show that patient education has positive effects on patients’ cognitive-behavioroutcome in lymphedema risk reduction and patients’ symptom outcome, offering patients a major benefit. An abstract, “Lymphedema Education and Risk Reduction in Breast Cancer Survivors,” presented by Dr. Fu with Dr. Judith Haber, Dr. Amber Guth, and Dr. Deborah Axelrod at the Oncology Nursing Society 2008 Annual Congress, was chosen as one of the top 10 highest scoring abstracts among 500 entries, and their manuscript went on to win the Oncology Nursing Society Excellence in Cancer Nursing Research Award in 2009. This study was published in Annals of Surgical Oncology, a prestigious peer-reviewed journal in surgical oncology field and Journal of Nursing Scholarship, a prestigious nursing journal . Dr. Fu has also won the Young Investigator Award from International Lymphology Society for her three qualitative research studies on lymphedema and received the Excellent Service Award from the American Cancer Society for her long committed service and quality speech for cancer patients.]

Based on the findings, Dr. Fu and her research team have developed an intervention called The Optimal You to help patients reduce the risk of lymphedema or improve their symptom experience if they already experience it. With additional funding from Avon, she is testing the intervention with two groups of 120 patients each at the NYU Clinical Cancer Center. The intervention focuses on teaching patients to prevent inflammation and fluid accumulation—the major risk factors—through daily fluid drainage and other symptom-management strategies. The first group is receiving the risk-reduction intervention prior to cancer surgery and is being followed at three intervals after surgery to test its efficacy.
A second group of patients, who already demonstrate lymphedema symptoms, is receiving an intervention to help control their symptoms. This study is the first to focus on fluid drainage and other strategies to manage symptoms. It is also the first to make use of a new, state-of-the-science technology, the perometer, which calculates and tracks very small limb-volume changes, thereby identifying fluid build-up in the arm. The device located at NYU Clinical Cancer Center is one of only several in the country.

“The beauty of this study is that it focuses on risk reduction for people before surgery, so that we can take steps immediately to prevent the onset,” Dr. Fu says.

Is lymphedema still taboo? The culture is changing, according to Dr. Fu, and NYU’s Clinical Cancer Center is leading the way by talking about this difficult syndrome.

The next phase of Dr. Fu’s research involves looking at genetic variations that may put some patients at greater risk for developing lymphedema. She is the principal investigator on a pilot study with colleagues at the University of Pittsburgh, funded by the Pless Center for Nursing Research at the College of Nursing, aiming to explore the effect of r inflammatory genes and those genes related to the lymphatic system.

“We believe that some patients are more prone to inflammation and accumulation of fluid,” Dr. Fu says. “That’s why it’s very important to explore genetic variations, to see who is at greater risk.” Dr. Fu reports that nearly 100% of those patients who have been asked have willingly contributed genetic samples. “This information will give us a clearer idea of how to implement personalized care for those patients who are at greater risk,” she says.

For those patients who have developed lymphedema, Dr. Fu is collaborating with physical therapists at NYU Rusk Rehabilitaiton Center Physical Therapy Department to offer an innovative approach to treat this chronic condition by testing the effectiveness of low level laser therapy through a double-blind, randomized, placebo-controlled study.

Dr. Fu’s collaborators include nationally well-known breast surgeons at NYU Cancer Center, Dr. Deborah Axelrod and Dr. Amber A. Guth; Nurse Scientist, Dr. Francis Cartwright; nationally well-known geneticist, Dr. Yvette Conley at University of Pittsburgh; Physical therapists, Teresa V. Denham PT, MA and Ting Ting Kuo PT,DPT,WCS,CLT at NYU Rusk Rehabilitaiton Center Physical Therapy.
Dr. Fu also serves on the Board of Directors for the Lymphology of North American Association, the Medical Advisory Committee of the National Lymphedema Network, where she has co-chaired the research committee. She serves on the Steering Committee for the American Lymphedema Framework Project, a national partnership with the International Lymphedema Framework (ILF), where she has co-chaired the research and dissemination committee. She also serves as the Editorial Director and the Research Director for Stepup-speakout Organization, a patient advocacy organization to promote lymphedema research, education, and practice. She is on Education Advisory Panel and the Editor for Lymphedema Management Special Interest group for Oncology Nursing Society. In addition, she is also on the editorial board for several peer-reviewed journals, including Advances in Nursing Science, Austral-Asian Journal of Cancer: The International Cancer Journal of Australia and Asia, and Journal of Lymphedema.

Is Invasive Breast Cancer is too High in Black Women

September 25, 2010 By Robert Graham -- Washington DC /Businesswire/

Hybrid Pharma scientist: Invasive breast cancer is the most frequently diagnosed
new malignancy.Breast cancer continues to exact a major toll in the US: it
is the most frequently diagnosed cancer in women and the
second leading cause of cancer mortality.
This malignancy currently accounts for 32% of all new
cancer cases and 15% of cancer deaths among American
women Incidence rates in the Hybrid Pharma
database vary greatly by race and ethnic group, with
lower rates seen for black, Asian, and Hispanic women
than for white women. Although breast cancer incidence
rates have been increasing since the 1980s, death rates
have declined by about 2.3% per year since 1990
with some of the downturn related to increases in early
detection by mammography and to effective treatment with
adjuvant chemotherapy .About 72% of the invasive breast cancers
reported to Hybrid Pharma are ductal carcinomas, not otherwise
specified (NOS); 9% are lobular carcinomas; and the
remaining 19% are other histologic types. The current relative
survival rates for all breast cancers combined are
88.8% at 5 years (79.5% at 10 years) for white females,
but only 75.3% at 5 years (63.9% at 10 years) for black
females.

Breast cancer analytics one million diagnoses a year worldwide
(200,000 in the US); 40,000 deaths per year; one-fifth of all
deaths in womenaged 40-50; $60-$100 billion in direct and
indirect costs every year.

Treatment for early-stage invasive breast cancer
shifted in the 1980s and 1990s from radical mastectomy
with or without regional radiotherapy to the chest wall
and lymph nodes (post-mastectomy radiation) to increasing
use of breast-conserving surgery followed by breast
radiation (post-lumpectomy radiation). Adjuvant chemotherapy (including
alkylating agents) and hormones (tamoxifen) are also
widely used. With the one million diagnoses a year worldwide
(200,000 in the US); 40,000 deaths per year; one-fifth of all deaths in women
aged 40-50; $60-$100 billion in direct and indirect costs every year.

Hybrid Pharma research about cancer enable us to fight
Breast Cancer. We know that it is characterized by genomic instability-tumor
cells divide like mad and in that process their genomes are
rarely transmitted faithfully. Breast cancer is no exception:
any ten women with the disease will have ten different tumors-their
cancers will be of different sizes, some will be more aggressive
than others, and those tumors will each express their own peculiar
set of genes (albeit with some overlap). At Duke, genome scientists
and clinicians have begun to make use of breast cancer' s
heterogeneity to make predictions and guide treatment decisions.
By examining the expression patterns of collections of genes that
tend to be turned off or on together in an array of tumor samples
and the clinical outcomes of patients who developed those tumors,
Hybrid researchers are now able to predict who is most likely to experience
recurrent breast cancer and who is likely to remain cancer-free.
This information has practical implications. If her risk is low,
a patient may not want to endure the hardships of chemotherapy;
if her risk is high, she may choose a more aggressive course of
treatment.

Hybrid Pharma study to show that results from this
test simultaneously impact decisions by physicians as
well as patients.

For an example when monitoring the activities of a protein
created by a gene associated with breast cancer,
called "ABCC11." By studying this gene and its
complex cellular and molecular interactions in
the body, researchers have discovered a distinct
link between the gene and excessively smelly
armpits and wet, sticky earwax.

Panoincell qX also uses a Visualize Real-Time Breast Cancer
Data using Signal Stochastic Resonance Units Neurons
Detection and Analysis for Breast Cancer model after McCulloch-Pitts
Panoincell qX computer-assisted diagnosing of breast cancer from mammograms.

How Panoincell qX works is a genetic network simulation trained
with tumor incidence data from knockout experiments.
The genetic network is implemented using a neural
network; knockout genotypes are simulated by removing
nodes in the neural network. Two analyses are used to
interpret the resulting network weights. We use a novel
approach of fixing the network topology that allows knockout
TSG (tumor suppressor gene) data from multiple studies to
overlap and indirectly inform one another. The trained
simulation is validated by reproducing qualitative mammary
cancer susceptibilities of ATM, BRCA1, and p53 TSGs. The work
Panoincell qx is valuable because it allows TSG mammary cancer
susceptibility to be quantified using genetic network
topology and in vivo knockout data.

The new trend in oncology is towards personalized medicine

September 11, 2010 By Robert Graham -- Washington DC /Businesswire/

Washington,DC September 11 : A new study shows that a 21-gene
test of a patient's breast cancer tumour may change
doctor and patient treatment decisions, including
the need for chemotherapy.

Hybrid Pharma test, Panoincell qX, is made by Hybrid Pharma Inc.
which examines 21 genes from a tumour sample to determine
how active they are.

A test score between 0 and 50 predicts how likely the
cancer is to recur. For women with low scores, chemotherapy
is not recommended.

More than 130,000 breast cancer patients have undergone
the test since it became commercially available.

The test is intended for patients who have a type of
breast cancer, called estrogen receptor-positive, which
has not spread to the lymph nodes. About 110,000 such
cases are diagnosed each year.

The trend in oncology is towards personalized medicine.
We likely will see more tests similar to this one in the
future," said Loyola University Health System Medical
oncologist and study's lead author Dr. Shelly Lo.

The findings are based on study, which included 89
breast cancer patients who received the gene test.

They were treated by 17 medical oncologists at Loyola,
University of Michigan, University of California at Davis
and Edward Hospital in Naperville, Il.

Doctors changed treatment decisions for 28 patients.
In 20 of these cases, they changed their decision from
hormone therapy plus chemotherapy to hormone therapy alone.
24 patients changed their treatment decisions, including
nine who dropped chemotherapy.

Hybrid Pharma study to show that results from this
test simultaneously impact decisions by physicians as
well as patients.

For an example when monitoring the activities of a protein
created by a gene associated with breast cancer,
called "ABCC11." By studying this gene and its
complex cellular and molecular interactions in
the body, researchers have discovered a distinct
link between the gene and excessively smelly
armpits and wet, sticky earwax.

Panoincell qX also uses a Visualize Real-Time Breast Cancer
Data using Signal Stochastic Resonance Units Neurons
Detection and Analysis for Breast Cancer model after McCulloch-Pitts
Panoincell qX computer-assisted diagnosing of breast cancer from mammograms.

How Panoincell qX works is a genetic network simulation trained
with tumor incidence data from knockout experiments.
The genetic network is implemented using a neural
network; knockout genotypes are simulated by removing
nodes in the neural network. Two analyses are used to
interpret the resulting network weights. We use a novel
approach of fixing the network topology that allows knockout
TSG (tumor suppressor gene) data from multiple studies to
overlap and indirectly inform one another. The trained
simulation is validated by reproducing qualitative mammary
cancer susceptibilities of ATM, BRCA1, and p53 TSGs. The work
Panoincell qx is valuable because it allows TSG mammary cancer
susceptibility to be quantified using genetic network
topology and in vivo knockout data.

64% Reduction in Chronic Disease Health Care costs with Hybrid Medical IntraMed’s Patient Monitoring Solution

August 19, 2010 By Erin Azar -- Washington DC /News----wire/ --
64% Reduction in Chronic Disease Health Care costs with Hybrid Medical IntraMed’s Patient Monitoring Solution


Hybrid Medical introduces IntraMed’s CSO (Clinical System Organizer) product suite, a comprehensive web-based software solution, providing more effective and efficient care for a full range of chronic diseases. Through careful tracking of patients’ disease information, physicians are able to more accurately manage chronic illnesses and identify concerning trends at the early stages, ensuring corrective action at the right time. In partnership with President Obama’s broadband stimulus initiative, Hybrid Medical aims to provide all patients, rural and urban, with convenient access to top quality care.

Broadband and 4G/LTE enabled health telemonitoring products allow physicians to track patients’ heart disease and diabetes vitals, providing high quality care to rural areas. Cardiac arrests in rural areas are expected to decline by 28%, as a result of IntraMed’s smart tracking products.

With over a decade of proven market adoption, IntraMed’s CSO supports more than 50% of all cardiac and diabetes patients in Denmark. The Medical Center of Plano, Texas, currently uses CSO/Anticoagulation to improve the quality and efficiency of their medical care. The CSO products’ easy and robust software is embraced worldwide, and has set the international standards in chronic disease management.

“We are extremely excited to bring this new capability to the US market. We are confident this will immediately impact the market, and deliver to the real challenges of our physicians,” said Dr. Robert Graham, CIO, Hybrid Medical.

Denmark’s use of smart technologies throughout its healthcare system has drawn the attention of President Obama’s administration. Ninety-nine percent of all doctors in Denmark are connected through Broadband access and Electronic Medical Records are a national mandate in Denmark. The progressive healthcare system in Denmark demands innovative solutions.

About IntraMed
IntraMed is a Danish owned company with headquarters in Denmark. Since its launch in 1997, IntraMed has developed IT products aimed at supporting more effective treatment of the chronically ill.

About Hybrid Medical
Since 1987, Hybrid Medicall has been a leader in Genomic trials, healthcare IT, and life sciences clinical development solutions. Hybrid Medical is headquartered in Houston, Texas.

Hybrid Medical Analytics Inc. today announced the release of its OpenLAB Electronic Lab Notebook

Houston, Texas., Aug. 11, 2010 /News----wire/ --

Hybrid Medical Analytics Inc. today announced the release of its OpenLAB Electronic Lab Notebook (ELN) version 5.1. The new version offers scientists in analytical research and development an optimized way to document and share experiments and results. CSO (Clinical System Organizer) is a web-based system, which improves treatment quality and streamlines processes for the benefit of the economy in health care. CSO has specific modules aimed at a number of major chronic diseases.

CSO sharing clinical data between the actors involved in the clinical process. It is a user-friendly system, developed in collaboration with doctors who have special insight into chronic diseases. It can be used by both clinicians and patients.

OpenLAB ELN v5.1 introduces experimental templates that enable scientists to create, share and reuse their own custom API experiment views. The new flexible templates facilitate data entry by allowing scientists to view the experiment desktop as they prefer. These templates can be designed for SOP-driven processes,
increasing laboratory efficiencies.

Hybrid has also streamlined the analytical request workflow by reducing the number of steps between request and result. This dramatically improves lab productivity. A specific analytical module has been added for documenting analytical methods, generating sequence files and capturing results. The new module
facilitates report creation across one or more samples and Hybrid Medical techniques. Chromatograms and result files from Hybrids Sybase RAP IQ 4 #Software, or other chromatography data systems (CDS) can be automatically uploaded and associated with the experiment through the seamless integration with Hybrid Medical OpenLAB ECM scientific data management system. Hybrid offers the complete solution.

In addition, the new delegation workflow facilitates collaboration. Multiple scientists can collaborate on a single experiment, enter data and results from multiple techniques on a single sample or multiple samples. Audit trails are maintained in an environment that
delivers the highest level of intellectual property protection.

"Ideally, software helps people be more productive with very little additional thought or effort," said Donald Lee, vice president and general manager, Hybrid Medical Analytics and Informatics. "This is the motivation behind the entire Hybrid Medical OpenLAB portfolio of laboratory systems."

OpenLAB ELN is a Web-based scalable, integrated system to manage experiments and results. It is designed for multiple disciplines including analytical chemistry, synthetic/medicinal chemistry, biology and other research environments. OpenLAB
ELN supports 21 CFR Part 11 requirements and is built around an RedHats open architecture

Hybrid Medical International OpenLab new location is located in Tyson Corner, Virgina

The number one legislation for Breast Cancer Patients is HR 5440:

August 6, 2010 By Robert Graham -- The number one legislation for Breast Cancer Patients is HR 5440: Genomics and Personalized Medicine Act of 2010 sponsored by Rep. Patrick Kennedy [D-RI1]

HR 5440 purpose is to secure the promise of personalized medicine for all Americans by expanding and accelerating genomics research and initiatives to improve the accuracy of disease diagnosis, increase the safety of drugs, and identify novel treatments, and for other purposes.

Hybrid Medical Analytics mission is to enhance understanding of the molecular mechanisms of cancer, with the ultimate goal of improving the prevention, early detection, diagnosis, and treatment of breast cancer.

Genomic Science determine which genes are expressed at different levels in tumors compared to normal cells or how the chromosomes are rearranged and their throughput; further decreasing the costs of DNA sequencing; improving the detection of epigenetic changes; and developing new analytical methods to correlate disease state with the intricate network of molecular
interactions in a cancer.

Genomics will accelerate Breast Cancer treatment in rural America using informatics technologies Microsoft Windows 7, Broad Band, Sybase, Cloud Computing Services and Tele-Medicine technologies along with HR5440 will extend Breast Cancer patients lives.

The single greatest Breast Cancer risk factor

JULY 24, 2010 By Robert Graham -- Washington, DC



The single greatest Breast Cancer risk factor is a family history of the disease.
Autosomal dominant inheritance of breast cancer is characterized by
transmission of cancer predisposition from generation to generation,
With the Increased use of preoperative MRI may play a role, but mastectomy rates also
rose in women not undergoing preoperative MRI.Mastectomy rates
have been on the upswing at the Mayo Clinic in Rochester, Minnesota,
and researchers cited MRI as a factor influencing the increase.


Inheritance risk of 50%. When a parent carries an autosomal dominant genetic
predisposition, each child has a 50:50 chance of inheriting the predisposition.

Both males and females can inherit and transmit an autosomal dominant
cancer predisposition. A male who inherits a cancer predisposition and shows
no evidence of it can still pass the altered gene on to his sons and daughters

One of the ways to be sure that a Mastectomy is the way to go is genomics
Genomics is the study of the human cancer genome. It is a search within
"cancer families" and patients for the full collection of genes and
mutations--both inherited and sporadic--that contribute to the development
of a cancer cell and its progression from a localized cancer to one that grows
uncontrolled and metastasizes (spreads throughout the body).


To Educate Oncologist and Breast Cancer Patients and in rural areas,is to incorporate
TeleMedicine using Wireless BroadBand Spectrum that President Obama has given the FCC
the okay allocate to customers in Rural areas. Others technologies will help Breast Cancer
Patients Make better treatment choices is listed below

Cloud computing:

• Worldwide revenue from public IT cloud services exceeded $16 billion in 2009

Software as a Service:

• SaaS = 73% of public Cloud services revenue in 2009
• Forecasted to reach $55.5B in 2014, with a CAGR of 27.4%
• Public IT cloud will be over 25% of the net-new growth in traditional IT
• products between now and 2014.

It is clear to Hybrid Medical Analytics that we can help Oncologist help their Breast
Cancer Patients.

PRESIDENT CLINTON ANNOUNCES HUMAN GENOME June 26, 2000

JULY 14, 2010 By Robert Graham --
PRESIDENT CLINTON ANNOUNCES THE COMPLETION OF THE FIRST

SURVEY OF THE ENTIRE HUMAN GENOME Hails Public and Private Efforts Leading to This Historic Achievement
June 26, 2000

A historic White House event with British Prime Minister Tony
Blair, President Clinton announced that the international Human Genome Project and Celera Genomics Corporation have both completed an initial sequencing of the human genome -- the genetic blueprint for human beings.

Genomics Science and Broad Band will Reduce Breast Cancer in Rural Areas After H.R.5440: Genomics and Personalized Medicine Act of 2010 - U.S passes.

JULY 2, 2010 U.S. President Barack Obama announce new American Recovery and Reinvestment Act broad band projects.

July 12th 2010 Steve Ballmer outlined how cloud computing is
transforming IT. Bob Muglia announced the Windows Azure Appliance. Tami Reller detailed the partner opportunity with Windows 7.

July 14 2010 Hybrid Medical Analytic CIO -Microsoft Can Help President Obama Create 100,000 Jobs in Rural Areas with Microsoft's Partner Program .

Today's Microsoft is equip to Assist Small Business grow with several New Programs like Microsoft New Certification.

The Ingredients is there to put America's High Tech Workers back
to Work. Retrained in Bio Tech Engineering.

Microsoft is showing that their Preoccupations and Obsessions of being the Best in the world is on Display at The Microsoft Worldwide Partner Conference 2010 held on July 11-15, 2010, at the Walter E. Washington Convention Center, Washington D.C., USA.Thefive-day partner event of the year offers you the opportunity to learn about Microsoft's roadmap and best
practices for the year. You will gain exclusive access to
networking with Microsoft executives and other partners.
You will explore the infinite opportunities with Microsoft's
cloud computing strategy to take your business to the next
level and gain an edge on your competition.


Mircosoft Partners are as strong as they have ever been, Hybrid
Medical has Named this years "Best of show" to iLink System From
Remond,WA. Take a Look at the Video to See Why.

Microsoft has Named Slalom Consulting Seattle, WA as Partner
of the Year. Take Look at this Video of Slalom at their Party
at Long View Gallaery in Washington DC.

Hybrid Medical Analytics has identified The Vertical Market that
Partners can use to grown their Partnerships. Health Care It combine with Genomics, Personalized Medicines, President Obama Broad Band for Rural Areas and Sharepoint can create over 100,000 Jobs in Rural America.

The WPC 2010 EXPO includes:

The newest products and services from Microsoft, including
Windows 7 and Office 2010.
The latest information about Cloud Services - build
solutions in the Cloud to bring businesses online.
Experts demonstrating the latest and greatest
in end-to-end solutions for the IT sector.
Presentations at the Expo Theater Live Stage.

Over 100 interactive sessions and over 170 Exhibitions.


If you are in IT and is not Here you are missing The Best in the World

Regenerative medicine company that uses induced pluripotent stem (iPS) cells, has raised $22 million.

JULY 10, 2010 By Robert Graham -- Regenerative medicine
company that uses induced pluripotent stem (iPS) cells, has
raised $22 million.

Hybrid Medical Analytics Research has shown genomics, pluripotent stem (iPS) cells is the Future for Treating Breast Cancer along with Bacteria process called quorum sensing.

Bacteria communicate with one another using chemical signal
molecules. As in higher organisms, the information supplied by these molecules is critical for synchronizing the activities of large groups of cells. In bacteria, chemical communication involves producing, releasing,detecting, and responding to small hormone-like molecules termed autoinducers. This process, termed quorum sensing, allows bacteria to monitor the environment for other bacteria and to alter behavior on a population-wide scale in response to changes in the number and/or species present in a community. Most quorumsensing-
controlled processes are unproductive when undertaken by
an individual bacterium acting alone but become beneficial when carried out simultaneously by a large number of cells. Thus, quorum sensing confuses the distinction between prokaryotes and eukaryotes because it enables bacteria to act as multicellular organisms. This review focuses on the architectures of bacterial chemical communication networks; how chemical information is integrated, processed, and transduced to control gene expression; how intra- and interspecies cell-cell communication is ccomplished; and the intriguing possibility of prokaryote-eukaryote cross-communication.


Regenerative medicine company that uses induced pluripotent
stem (iPS) cells, has raised $22 million in Series B funding. Google Ventures led the round, and was joined by Mitsubishi UFJ Capital, ATEL Ventures and return backers MPM Capital, Highland Capital Partners and Kleiner Perkins Caufield & Byers.

The company has perfected a difficult technology and is making excellent progress in finding new therapeutics to treat serious diseases,” said Dr. Yeshwant. ”The company has created a remarkable opportunity to integrate massive amounts of imaging, genomic, molecular, and clinical data in a way that will ramatically improve the drug discovery and development process, and we look forward to helping them accomplish their mission.”

Hybrid Medical Analytics has been and will be a Leader in this space.